Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with non-small cell lung cancer exhibiting epidermal growth factor receptor mutations: A case report.

Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with non-small cell lung cancer exhibiting epidermal growth factor receptor mutations: A case report. Oncol Lett. 2018 Jul;16(1):1046-1050 Authors: Yamaguchi T, Gotoh Y, Hattori H, Katsuno H, Imaizumi K Abstract A previous randomized phase II study in patients with non-small cell lung cancer (NSCLC) identified that combination treatment with erlotinib plus bevacizumab prolonged progression-free survival compared with erlotinib alone. However, combination bevacizumab and erlotinib treatment generally increased the risk of severe adverse events, including hemorrhage, thrombosis, fistula formation and gastrointestinal perforation. The present report describes two patients with NSCLC harboring epidermal growth factor receptor (EGFR) mutations, who experienced gastrointestinal perforation associated with erlotinib plus bevacizumab combination therapy. The first patient, a 67-year-old male with stage IIIB lung adenocarcinoma harboring a L858R point mutation in EGFR exon 21, received concurrent chemoradiotherapy. However, seven months later, the patient experienced a relapse and was administered erlotinib plus bevacizumab treatment. A total of two months subsequent to commencing treatment, the patient developed a perforated duodenal ulcer. The second patient, a 66-year-old male with lung adenocarcinoma harboring a deletion in EGFR exon 19 and multiple pulmonary metastas...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Related Links:

This study investigated the protein expression profile of STC1 in PCa and benign prostatic hyperplasia (BPH) samples and STC1 signalling during cell proliferation and cell death in vitro using cell lines. We found higher levels of STC1 in PCa when compared to BPH tissue and that STC1 inhibited forskolin stimulation of cAMP in PC-3 cells. A monoclonal antibody against STC1 was effective in reducing cell proliferation, in promoting cell cycle arrest, and in increasing apoptosis in the same cells. Since STC1 acts as a regulator of prostatic tissue signalling, we suggest that this protein is a novel candidate biomarker for p...
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
CONCLUSIONS: CNB and SSNB have similar effects on pain relief, complications and functional recovery in patients receiving TKA. The optimal analgesic regimen for patients after TKA needs further identification. PMID: 31808660 [PubMed - as supplied by publisher]
Source: Minerva Anestesiologica - Category: Anesthesiology Tags: Minerva Anestesiol Source Type: research
Publication date: Available online 6 December 2019Source: Trends in Pharmacological SciencesAuthor(s): Lorenzo GalluzziAlthough somatic KRAS mutations are common in human tumors, no inhibitor of mutant KRAS was clinically available until recently. Canon and colleagues describe the ability of a clinically available KRASG12C inhibitor to drive immunogenic cancer cell death, thus constituting a promising combinatorial partner for immune checkpoint blockers.
Source: Trends in Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research
ConclusionABCB1 C3435T and ABCG2 C421A might represent a potential risk factor for breast cancer for Turkish women.
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
ConclusionThe findings suggest that chitosan, as a prime drug-delivery carrier, significantly alleviates the acute and sub-acute toxic effects of 6-MP.
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
ConclusionResults of this study demonstrated the potential of MWL oil in the development of natural anticancer therapeutic agents.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 6 December 2019Source: International Journal of PharmaceuticsAuthor(s): Iftikhar Khan, Maria Apostolou, Ruba Bnyan, Chahinez Houacine, Abdelbary Elhissi, Sakib S YousafAbstractA simplistic approach was conducted to manufacture novel paclitaxel (PTX) loaded protransfersome tablet formulations for pulmonary drug delivery. Large surface area presented by pulmonary system offer better target using anti-cancer drug deposition for localized effect in the lungs. Protransfersomes are dry powder formulations, whereas transfersomes are liquid dispersions containing vesicles generated from protransf...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Conclusion: These results conclude that G.A has the potential to reduce metastatic melanoma through its anti-proliferative and anti-metastatic effects.Graphical abstract
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 22 October 2019Source: Seminars in Cancer BiologyAuthor(s): Tamara T. Lah, Metka Novak, Barbara BreznikAbstractBrain, the major organ of the central nervous system controls and processes most of body activities. Therefore, the most aggressive brain tumor – glioblastoma and metastases from other organs to the brain are lethal leaving the patients with very short time of survival. The brain tissue landscape is very different from any other tissues and the specific microenvironment, comprising stem cells niches and blood-brain barrier, significantly influences the low rate of glioblast...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: March 2020Source: Journal of Cancer Policy, Volume 23Author(s): Brandon Maser, Lisa M. Force, Paola Friedrich, Federico Antillon, Ramandeep S. Arora, Cristian A. Herrera, Carlos Rodriguez-Galindo, Rifat Atun, Avram DenburgAbstractTo help understand how health systems and sociopolitical contexts intersect with and impact the performance of childhood cancer care in low- and middle-income countries (LMICs), we have developed a systems-level framework for analyzing the performance of LMIC childhood cancer programs within their health system contexts: The Paediatric Oncology System Integration Tool (POSIT). PO...
Source: Journal of Cancer Policy - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Avastin | Cancer | Cancer & Oncology | CT Scan | Diverticular Disease | Duodenal Ulcer | Gastroenterology | Gastroschisis Repair | Lung Cancer | Non-Small Cell Lung Cancer | Pain | Pulmonary Thromboembolism | Study | Tarceva | Thrombosis